15 May Cambridge Major to build new pharma plant
Germantown, Wis. – Cambridge Major Laboratories says it will build a new 120,000-square-foot plant next to its Germantown headquarters, enabling the company to expand into large-scale active pharmaceutical ingredient manufacturing.
The facility, which will contain multiple manufacturing suites that are capable of making multi-ton quantities of active pharmaceutical ingredients (APIs), is scheduled for completion in August of 2009.
Since opening a small-volume manufacturing site in 2004, Cambridge Major has built a growing pipeline of APIs, but it now needs more capacity for later-stage clinical and commercial production. It already has three API development sites in the United States and Europe, and they will feed large-scale manufacturing at the new site.
Michael Major said it’s “vitally important” for the company to extend its service offerings because it has a number of projects in Phase III clinical trials. The company, established in 1999, wants to continue on the 30 percent annual growth rate it has experienced since its inception.
Related stories
• Cambridge Major acquires Netherlands pharma company
• Cambridge Major appoints Hartwig as scientific advisor
• Germantown drug company hires pharma veteran James Davidson as COO